# Clinical Study of JDB0131 Benzenesulfonate Tablets in Patients With Drug-sensitive Pulmonary Tuberculosis

> **NCT06224036** · PHASE2 · UNKNOWN · sponsor: **Beijing Chest Hospital** · enrollment: 52 (estimated)

## Conditions studied

- Drug-resistant Tuberculosis

## Interventions

- **DRUG:** JDB0131
- **DRUG:** Delamanid
- **DRUG:** Ethylpyrazine rifampicide (II)

## Key facts

- **NCT ID:** NCT06224036
- **Lead sponsor:** Beijing Chest Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-10-31
- **Primary completion:** 2024-03-31
- **Final completion:** 2024-03-31
- **Target enrollment:** 52 (ESTIMATED)
- **Last updated:** 2024-01-25

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06224036

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06224036, "Clinical Study of JDB0131 Benzenesulfonate Tablets in Patients With Drug-sensitive Pulmonary Tuberculosis". Retrieved via AI Analytics 2026-06-22 from https://api.ai-analytics.org/clinical/NCT06224036. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*